Tandem Diabetes (TNDM) Prelim. Q4 Revenue Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Tandem Diabetes Care Announces Preliminary 2017 Results and Provides 2018 Guidance
January 9, 2018 4:15 PM ESTGuidance for 2018 Reflects Expectation of Continued Growth
SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported select, unaudited and preliminary results for the year and quarter ended December 31, 2017.
In comparing the fourth quarter of 2017 to the same period of 2016:
GAAP sales increased to approximately $39 million to $40 million from $28.9 million Non-GAAP sales increased to approximately $39 million to $40 million from $24.8 million Pump shipments increased to... More